SARS-CoV-2 multisystem inflammatory syndrome in an adult presenting with polyarthritis treated with anakinra

Rheumatology (Oxford). 2022 Feb 2;61(2):e33-e34. doi: 10.1093/rheumatology/keab697.

Authors

Varun Chalasani¹, Padmini Parameswaran², Adriani Cherico¹, Vipin Villgran³, Holly Lowther², Joanna Marco²

Affiliations

¹ Department of Internal Medicine.
² Department of Rheumatology.
³ Department of Pulmonology, Allegheny Health Network, Pittsburgh, PA, USA.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antirheumatic Agents / therapeutic use
Arthritis / drug therapy*
Arthritis / virology*
COVID-19 / complications*
COVID-19 Drug Treatment*
Glucocorticoids / therapeutic use
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Male
Methylprednisolone / therapeutic use
Middle Aged
Pandemics
SARS-CoV-2
Systemic Inflammatory Response Syndrome / drug therapy*

Substances

Antirheumatic Agents
Glucocorticoids
Interleukin 1 Receptor Antagonist Protein
Methylprednisolone

Supplementary concepts

adult multisystem inflammatory disease, COVID-19 related